Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Replimune Group Inc REPL

Healthcare Biotechnology
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a... see more

Recent & Breaking News (NDAQ:REPL)

Replimune Announces Pricing of Upsized Public Offering

GlobeNewswire October 22, 2020

Replimune Announces Proposed Public Offering

GlobeNewswire October 20, 2020

Replimune Releases Updated Corporate Presentation

GlobeNewswire October 20, 2020

Replimune Appoints Tanya Lewis to the Board of Directors

GlobeNewswire October 19, 2020

Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire October 14, 2020

Replimune to Participate at the Chardan Virtual 4th Annual Genetic Medicines Conference

GlobeNewswire October 1, 2020

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

GlobeNewswire August 7, 2020

Replimune to Present at Two Upcoming Investor Conferences

GlobeNewswire August 4, 2020

Replimune Appoints Andrea Pirzkall, M.D. as Chief Medical Officer

GlobeNewswire July 22, 2020

Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

GlobeNewswire June 17, 2020

Replimune Announces Pricing of Upsized Public Offering

GlobeNewswire June 8, 2020

Replimune Announces Proposed Public Offering

GlobeNewswire June 8, 2020

Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

GlobeNewswire June 3, 2020

Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune's Ongoing Registration-Directed Clinical Trials with RP1

GlobeNewswire June 3, 2020

Replimune to Provide Data Update on June 3, 2020

GlobeNewswire April 30, 2020

Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors

GlobeNewswire April 2, 2020

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

GlobeNewswire February 13, 2020

Replimune to Present at Two Upcoming Investor Conferences

GlobeNewswire February 6, 2020

Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones

GlobeNewswire January 13, 2020

Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization

GlobeNewswire January 9, 2020